Boron -- Topical & Dietary
randall
Hi,
Where did i get that boron thing?
Last post at the sign off.
Boron for PSOR morons?
But it works for some of us?
Just not for psor...
http://groups.google.com/group/alt.support.skin-diseases.psoriasis/msg/00623c4f6d27970c
LOOKing for boron?
Here's another.
www.ncbi.nlm.nih.gov/pubmed/19876791
AN-2728, a PDE4 inhibitor for the potential topical treatment of
psoriasis and atopic dermatitis.
Nazarian R, Weinberg JM.
St Lukes-Roosevelt Hospital Center, Department of Dermatology, 1090
Amsterdam Avenue, Suite 11D, New York, NY 10025, USA.
rnaz...@chpnet.org
Cytokines are signaling molecules that are believed to be key factors
in perpetuating the inflammatory process in psoriasis and atopic
dermatitis. AN-2728, being developed by Anacor Pharmaceuticals Inc, is
a topically administered, ______boron-containing_____, anti-
inflammatory compound that inhibits PDE4 activity and thereby
suppresses the release of TNFalpha, IL-12, IL-23 and other cytokines.
At the time of publication, three phase Ib clinical trials, a IIa
trial and a IIb trial of AN-2728 in patients with psoriasis had been
completed; the compound was also undergoing phase II development for
atopic dermatitis, but no data were available for this indication.
AN-2728 was reported to be well tolerated and to demonstrate
significant effects on markers of efficacy, with results that were
comparable to positive controls. AN-2728 appears to have good
therapeutic potential, although further and larger trials are required
to assess the long-term safety and characterize the broad utility of
this drug.
PMID: 19876791
Do these PDE4 inhibitors work?
www.ncbi.nlm.nih.gov/pubmed/19832118
[...]
best progress has been achieved recently with the oral, non-isoform
selective PDE4 inhibitor roflumilast.
PMID: 19832118
Do i need to ferret this out?
www.ncbi.nlm.nih.gov/pubmed/19853596
Luteolin, a non-selective competitive inhibitor of phosphodiesterases
1-5, displaced [(3)H]-rolipram from high-affinity rolipram binding
sites and reversed xylazine/ketamine-induced anesthesia.
Yu MC, Chen JH, Lai CY, Han CY, Ko WC.
Department of Internal Medicine, Taipei Municipal Wan-Fang Hospital,
Taiwan.
The aim of the present study was to investigate the mode of action of
luteolin on phisphodiesterase (PDE) 1-5, and the possible adverse
effects, such as nausea, vomiting, and gastric hypersecretion,
determined by replacing [(3)H]-rolipram binding and reversing xylazine/
ketamine-induced anesthesia. The reversing effect was reported to
occur through a presynaptic alpha(2)-adrenoceptor inhibition and
trigger vomiting in ferrets. In contrast, clonidine, an alpha(2)-
adrenoceptor agonist, prevented emesis induced by PDE4 inhibitors in
ferrets. According to the Lineweaver-Burk analysis, luteolin (3-30muM)
competitively inhibited PDE1-5 activities, with K(i) values of 15.0,
6.4, 13.9, 11.1, and 9.5muM, respectively, which did not significantly
differ from each other. The equilibrium dissociation constant (K(d))
and maximal density (B(max)) for [(3)H]-rolipram binding at high-
affinity rolipram binding sites of guinea pig brain cell membranes
were 10.1nM and 3.7pmol/g of tissue, respectively. The EC(50) (PDE4
(H)) values of luteolin and Ro 20-1724, a selective PDE4 inhibitor,
for displacing 2nM [(3)H]-rolipram binding were 11.2muM and 45.6nM,
respectively. The therapeutic (PDE4(H)/PDE4(L)) ratios of luteolin and
Ro 20-1724 were calculated to be 0.6, and 0.004, respectively. Both
luteolin (10-30mumol/kg, s.c.) and Ro 20-1724 (0.1-1mumol/kg, s.c.)
significantly reversed the xylazine/ketamine-induced anesthesia in
mice. Although luteolin non-selectively and competitively inhibited
PDE1-5, only PDE4 inhibition contributed to a reversing effect. In
conclusion, because of the low therapeutic (PDE4(H)/PDE4(L)) ratio of
luteolin, the gastrointestinal adverse effects such as nausea,
vomiting and gastric hypersecretion should be carefully monitored,
whenever luteolin is used for treating allergies, asthma or chronic
obstructive pulmonary disease.
PMID: 19853596
How much celery and parsley do I have to eat? LOL
================
Let's look at the pandemic instead. I haven't spoken with ONE person
with the flu or swine flu
so far.
Is there a flu forum like the NPF?
Mercola and the ongoing swine flu drama:
http://articles.mercola.com/sites/articles/archive/2009/10/31/CDC-Says-Kids-That-Die-From-Swine-Flu-Have-Coexisting-Bacterial-Infections.aspx
Very interesting.
I went to my local Kaiser health guys and they had two tables set up
to give shots.
So I asked if I could get one and if not then when?
They said sorry, but there facility on vandever had them for the
general public
but they said the lines would be un real.
So i went to my exercise class and the teacher said we could use our
chi (Qi) to
simply block the evil viral bugs.
But i'd rather use www.longevinex.com resveratrol as my vaccine.
And a sip of red wine. LOL
--------------
STAY HEALTHY AND CLEAR
drink dos equis. LOL
===============
Still looking at L Plantarum
www.ncbi.nlm.nih.gov/pubmed/19638173
Lifestyle of Lactobacillus plantarum in the mouse caecum.
Marco ML, Peters TH, Bongers RS, Molenaar D, van Hemert S, Sonnenburg
JL, Gordon JI, Kleerebezem M.
TI Food and Nutrition, Nieuwe Kanaal 9A, 6709 PA, Wageningen, The
Netherlands.
Lactobacillus plantarum is a common inhabitant of mammalian
gastrointestinal tracts. Strains of L. plantarum are also marketed as
probiotics intended to confer beneficial health effects upon delivery
to the human gut. To understand how L. plantarum adapts to its gut
habitat, we used whole genome transcriptional profiling to
characterize the transcriptome of strain WCFS1 during colonization of
the caeca of adult germ-free C57Bl/6 J mice fed a standard low-fat
rodent chow diet rich in complex plant polysaccharides or a prototypic
Western diet high in simple sugars and fat. Lactobacillus plantarum
colonized the digestive tracts of these animals to high levels,
although L. plantarum was found in 10-fold higher amounts in the caeca
of mice fed the standard chow. Metabolic reconstructions based on the
transcriptional data sets revealed that genes involved in carbohydrate
transport and metabolism form the principal functional group that is
upregulated in vivo compared with exponential phase cells grown in
three different culture media, and that a Western diet provides a more
nutritionally restricted, growth limiting milieu for the microbe in
the distal gut. A set of bacterial genes encoding cell surface-related
functions were differentially regulated in both groups of mice. This
set included downregulated genes required for the d-alanylation of
lipoteichoic acids, extracellular structures of L. plantarum that
mediate interactions with the host immune system. These results,
obtained in a reductionist gnotobiotic mouse model of the gut
ecosystem, provide insights about the niches (professions) of this
lactic acid bacterium, and a context for systematically testing
features that affect epithelial and immune cell responses to this
organism in the digestive tract.
PMID: 19638173
http://www.biomedcentral.com/1471-2164/9/374/figure/F2?highres=y
Troost et al***
So does this go with the above?
www.ncbi.nlm.nih.gov/pubmed/18681965
Identification of the transcriptional response of human intestinal
mucosa to Lactobacillus plantarum WCFS1 in vivo.
___Troost FJ___***, van Baarlen P, Lindsey P, Kodde A, de Vos WM,
Kleerebezem M, Brummer RJ.
Department of Internal Medicine, Division of Gastroenterology &
Hepatology, Maastricht University, Maastricht, The Netherlands.
f.tr...@intmed.unimaas.nl
BACKGROUND: There is limited knowledge on the extent and dynamics of
the mucosal response to commensal and probiotic species in the human
intestinal lumen. This study aimed to identify the acute, time-
dependent responses of intestinal mucosa to commensal Lactobacillus
plantarum WCFS1 in vivo in two placebo-controlled human intervention
studies in healthy volunteers. Transcriptional changes in duodenal
mucosa upon continuous intraduodenal infusion of L. plantarum WCFS1
for one- and six h, respectively, were studied using oro- and
nasogastric intubations with dedicated orogastric catheters and tissue
sampling by standard flexible gastroduodenoscopy. RESULTS: One- and
six-h exposure of small intestinal mucosa to L. plantarum WCFS1
induced differential expression of 669 and 424 gene reporters,
respectively. While short-term exposure to L. plantarum WCFS1
inhibited fatty acid metabolism and cell cycle progression, cells
switched to a more proliferative phase after prolonged exposure with
an overall expression profile characterized by upregulation of genes
involved in lipid metabolism, cellular growth and development. Cell
death and immune responses were triggered, but cell death-executing
genes or inflammatory signals were not expressed. Proteome analysis
showed differential expression of several proteins. Only the
microsomal protein 'microsomal triglyceride transfer protein' was
regulated on both the transcriptional and the protein level in all
subjects. CONCLUSION: Overall, this study showed that intestinal
exposure to L. plantarum WCFS1 induced consistent, time-dependent
transcriptional responses in healthy intestinal mucosa. This extensive
exploration of the human response to L. plantarum WCFS1 could
eventually provide molecular support for specific or probiotic
activity of this strain or species, and exemplifies the strength of
the applied technology to identify the potential bio-activity of
microbes in the human intestine.
PMID: 18681965 [PubMed - indexed for MEDLINE]
Troost is on to some GOOD Gi stuff:
http://www.ncbi.nlm.nih.gov/pubmed?term=%22Troost%20FJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract
A tryptophan serotonin Gut connect:
www.ncbi.nlm.nih.gov/pubmed/1965077
Brings up kynurenine pathway.
http://en.wikipedia.org/wiki/Kynurenine_pathway
http://en.wikipedia.org/wiki/File:KP_pathway.jpg
www.ncbi.nlm.nih.gov/pubmed/15541637
[...]
CONCLUSION: The tryptophan degradation pathway may play an important
role in the pathophysiology of AD and psoriasis.
PMID: 15541637
I love melatonin but find with less sunshine lately i don't need it.
I'm so sleepy i just fall right off the cliff in to dream land. yeah
right. <w>
www.ncbi.nlm.nih.gov/pubmed/19707587
Butyrate-induced transcriptional changes in human colonic mucosa.
Vanhoutvin SA, Troost FJ, Hamer HM, Lindsey PJ, Koek GH, Jonkers DM,
Kodde A, Venema K, Brummer RJ.
TI Food and Nutrition, Wageningen, The Netherlands.
s.vanh...@intmed.unimaas.nl
BACKGROUND: Fermentation of dietary fiber in the colon results in the
production of short chain fatty acids (mainly propionate, butyrate and
acetate). Butyrate modulates a wide range of processes, but its
mechanism of action is mostly unknown. This study aimed to determine
the effects of butyrate on the transcriptional regulation of human
colonic mucosa in vivo. METHODOLOGY/PRINCIPAL FINDINGS: Five hundred
genes were found to be differentially expressed after a two week daily
butyrate administration with enemas. Pathway analysis showed that the
butyrate intervention mainly resulted in an increased transcriptional
regulation of the pathways representing fatty acid oxidation, electron
transport chain and oxidative stress. In addition, several genes
associated with epithelial integrity and apoptosis, were found to be
differentially expressed after the butyrate intervention. CONCLUSIONS/
SIGNIFICANCE: Colonic administration of butyrate in concentrations
that can be achieved by consumption of a high-fiber diet enhances the
maintenance of colonic homeostasis in healthy subjects, by regulating
fatty acid metabolism, electron transport and oxidative stress
pathways on the transcriptional level and provide for the first time,
detailed molecular insight in the transcriptional response of gut
mucosa to butyrate.
PMID: 19707587 [PubMed - in process]
You know. I'm gonna have to come back and look at this once
I do the trial.
http://www.biomedcentral.com/1471-2164/9/374/figure/F2?highres=y
And then try topical boron... or be a psor moron...
www.ncbi.nlm.nih.gov/pubmed/19303290
Discovery and structure-activity study of a novel benzoxaborole anti-
inflammatory agent (AN2728) for the potential topical treatment of
psoriasis and atopic dermatitis.
Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y,
Kimura R, Maples KR, Plattner JJ.
Anacor Pharmaceuticals, Inc, Palo Alto, CA 94303, USA.
tak...@anacor.com
A series of phenoxy benzoxaboroles were synthesized and screened for
their inhibitory activity against PDE4 and cytokine release. 5-(4-
Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed
potent activity both in vitro and in vivo. This compound is now in
clinical development for the topical treatment of psoriasis and being
pursued for the topical treatment of atopic dermatitis.
PMID: 19303290
JRStern
wrote:
>How much celery and parsley do I have to eat? LOL
A lot.
Anecdotal story of it working, but involves eating a pound or two a
day of celery.
Parsley is very high in vitamin A, and eating that much of it might be
contraindicated.
J.